Crescent Biopharma (NASDAQ:CBIO) Trading Down 5.1% – Should You Sell?

Crescent Biopharma, Inc. (NASDAQ:CBIO)’s stock price fell 5.1% during mid-day trading on Monday . The company traded as low as $16.93 and last traded at $16.8460. Approximately 13,978 shares were traded during mid-day trading, a decline of 95% from the average session volume of 265,922 shares. The stock had previously closed at $17.75.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Wedbush reaffirmed an “outperform” rating and set a $27.00 price target on shares of Crescent Biopharma in a research report on Thursday. HC Wainwright reissued a “neutral” rating on shares of Crescent Biopharma in a report on Thursday, July 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Crescent Biopharma in a research note on Friday, August 7th. Finally, TD Cowen raised shares of Crescent Biopharma to a “strong-buy” rating in a report on Monday, August 24th. Two investment analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Crescent Biopharma presently has an average rating of “Moderate Buy” and an average target price of $29.60.

Crescent Biopharma Stock Performance

The company has a market capitalization of $615.41 million, a P/E ratio of -2.47 and a beta of 1.23. The business has a 50 day moving average of $16.64 and a 200-day moving average of $16.60.

Crescent Biopharma (NASDAQ:CBIO) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.74). As a group, equities analysts forecast that Crescent Biopharma, Inc. will post -2.91 EPS for the current fiscal year.

Insider Activity

In related news, COO Jonathan Mcneill sold 20,549 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $17.99, for a total transaction of $369,676.51. Following the completion of the transaction, the chief operating officer owned 139,158 shares of the company’s stock, valued at approximately $2,503,452.42. The trade was a 12.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Joshua T. Brumm sold 42,305 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $17.99, for a total transaction of $761,066.95. Following the transaction, the chief executive officer directly owned 281,212 shares of the company’s stock, valued at approximately $5,059,003.88. This represents a 13.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 68,156 shares of company stock worth $1,226,126. Company insiders own 24.84% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. California State Teachers Retirement System purchased a new position in shares of Crescent Biopharma during the 2nd quarter valued at $96,000. Wellington Management Group LLP bought a new stake in Crescent Biopharma during the second quarter valued at $263,000. Stonepine Capital Management LLC bought a new stake in Crescent Biopharma during the second quarter valued at $720,000. Bank of America Corp DE purchased a new position in Crescent Biopharma during the second quarter worth about $465,000. Finally, ADAR1 Capital Management LLC purchased a new position in Crescent Biopharma during the second quarter worth about $329,000. 75.19% of the stock is owned by institutional investors.

About Crescent Biopharma

Crescent Biopharma, Inc (NASDAQ: CBIO) is a clinical‐stage immuno‐oncology company focused on the discovery, development and commercialization of novel therapies for patients with solid tumors. The company’s research strategy centers on combination approaches that enhance anti‐tumor immune responses by simultaneously targeting multiple pathways implicated in immune evasion and tumor growth.

The company’s lead candidate, CPB-201, is a bifunctional fusion protein designed to block programmed death-ligand 1 (PD-L1) while neutralizing transforming growth factor-beta (TGF-β), with the goal of restoring T-cell activity and reducing tumor fibrosis.